Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer

References

• CarlingTUdelsmanRThyroid tumorsDeVitaVTHellmanSRosenbergSACancer: Principles and Practice of OncologyPhiladelphia, PALippincott Williams & Wilkins2011
   Google Scholar
• HazardJBHawkWACrileGJrMedullary (solid) carcinoma of the thyroid; a clinicopathologic entityJ Clin Endocrinol Metab195919115216113620740
   PubMed Web of Science ®Google Scholar
• FriedellGHCareyRJRosenHFamilial thyroid cancerCancer19621524124513895201
   PubMed Web of Science ®Google Scholar
• SippleJHThe association of pheochromocytoma with carcinoma of the thyroid glandAm J Med1961311163166
   Web of Science ®Google Scholar
• SteinerALGoodmanADPowersSRStudy of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2Medicine (Baltimore)19684753714094386574
   PubMed Web of Science ®Google Scholar
• SakorafasGHFriessHPerosGThe genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomyEndocr Relat Cancer200815487188419015274
   PubMed Web of Science ®Google Scholar
• B BrandiMLGagelRFAngeliAGuidelines for diagnosis and therapy of MEN type 1 and type 2J Clin Endocrinol Metab200186125658567111739416
   PubMed Web of Science ®Google Scholar
• DottoriniMEAssiASironiMSangalliGSpreaficoGColomboLMultivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variablesCancer1996778155615658608543
   PubMed Web of Science ®Google Scholar
• RomanSLinRSosaJAPrognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 casesCancer200610792134214217019736
   PubMed Web of Science ®Google Scholar
• ScherublHRaueFZieglerRCombination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II studyJ Cancer Res Clin Oncol1990116121232312602
   PubMed Web of Science ®Google Scholar
• DeshpandeHAGettingerSNSosaJANovel chemotherapy options for advanced thyroid tumors: small molecules offer great hopeCurr Opin Oncol2008201192418043252
   PubMed Web of Science ®Google Scholar
• SchimkeRNHartmannWHFamilial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entityAnn Intern Med1965636102710395844561
   PubMed Web of Science ®Google Scholar
• TakahashiMRitzJCooperGMActivation of a novel human transforming gene, RET, by DNA rearrangementCell19854225815882992805
   PubMed Web of Science ®Google Scholar
• EngCRET protooncogene in the development of human cancerJ Clin Oncol199917138039310458257
   PubMed Web of Science ®Google Scholar
• CappCWajnerSMSiqueiraDRBrasilBAMeurerLMaiaALIncreased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinomaThyroid201020886387120615131
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res200262164645465512183421
   PubMed Web of Science ®Google Scholar
• CarlomagnoFVitaglianoDGuidaTZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinasesCancer Res200262247284729012499271
   PubMed Web of Science ®Google Scholar
• HerbstRSHeymachJVO’ReillyMSOnnARyanAJVandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesisExpert Opin Investig Drugs2007162239249
   PubMed Web of Science ®Google Scholar
• HoldenSNEckhardtSGBasserRClinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnn Oncol20051681391139715905307
   PubMed Web of Science ®Google Scholar
• TamuraTMinamiHYamadaYA phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumorsJ Thorac Oncol2006191002100917409986
   PubMed Web of Science ®Google Scholar
• WellsSAJrGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol201028576777220065189
   PubMed Web of Science ®Google Scholar
• RobinsonBGPaz-AresLKrebsAVasselliJHaddadRVandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Endocrinol Metab20109562664267120371662
   PubMed Web of Science ®Google Scholar
• WellsSARobinsonBGGagelRFVandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized double blind Phase III trial (ZETA) [abstract]J Clin Oncol20102815 Suppl Abst 5503
   Google Scholar
• Vandetanib (ZD6474) tablets Oncologic Drugs Advisory Committee (ODAC)Meeting Briefing Document 02 December 2010 Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdfAccessed October 31, 2011
   Google Scholar
• AhujaSErnstHChemotherapy of thyroid carcinomaJ Endocrinol Invest19871033033103624802
   PubMed Web of Science ®Google Scholar
• MatuszczykAPetersennSVoigtWChemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epitheliumHorm Metab Res2010421616419735058
   PubMed Web of Science ®Google Scholar
• GilliamLKKohnADLalaniTCapecitabine therapy for refractory metastatic thyroid carcinoma: a case seriesThyroid200616880181016910885
   PubMed Web of Science ®Google Scholar
• KurzrockRCohenEEShermanSILong-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET [abstract]J Clin Oncol20102815 Suppl Abst 5502
   Google Scholar
• SalgiaRShermanSHongDSA phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies including a subgroup of patients with medullary thyroid cancer (MTC) [abstract]J Clin Oncol200826 Suppl Abst 3522
   Web of Science ®Google Scholar
• SchlumbergerMJEliseiRBastholtLPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerJ Clin Oncol200927233794380119564535
   PubMed Web of Science ®Google Scholar
• DeshpandeHAGettingerSSosaJAAxitinib: The evidence of its potential in the treatment of advanced thyroid cancerCore Evid20104434820694064
   PubMedGoogle Scholar
• CohenEERosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyJ Clin Oncol200826294708471318541897
   PubMed Web of Science ®Google Scholar
• LamETRingelMDKloosRTPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerJ Clin Oncol201028142323233020368568
   PubMed Web of Science ®Google Scholar
• CarrLLMankoffDAGoulartBHPhase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlationClin Cancer Res201016215260526820847059
   PubMed Web of Science ®Google Scholar